CMA secures affordable supply of key bipolar drug
In October, the CMA launched an investigation suspecting that the pharmaceutical supplier, Essential Pharma, may have abused a dominant market position by adopting a strategy to withdraw the bipolar drug, Priadel, from UK patients. This would have cau… read more

